2006, Anxiety disorders and Depression treatment

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2006

Anxiety disorders

Depression treatment

Do Critics of Biological Psychiatry Have an Alternative to a Life of “Whack-A-Mole”?

Mad in America

MARCH 15, 2025

This turn to ketamine is occurring despite the fact that the Food and Drug Administration has repeatedly warned that the FDA has not approved ketamine for the treatment of any psychiatric disorder (though controversially approving esketamine nasal spray).

Neurotransmitters and mental health

Neurotransmitters and mental health Trauma and the brain Manufacturing Pharmaceuticals

STAR*D: The Harms of Orchestrated Psychiatric Fraud

Mad in America

SEPTEMBER 18, 2024

A few years ago, one in five US adults reported having ever received a diagnosis of depression. At a cost of 35 million dollars, NIMH’s STAR*D study, which was published in 2006 , is the most extensive and expensive study ever conducted to determine the effectiveness of drug treatment for depression.

Aging and mental health

Aging and mental health Cognitive Behavioral Therapy Manufacturing Anxiety disorders

Mental Health Clinicians

Do Critics of Biological Psychiatry Have an Alternative to a Life of “Whack-A-Mole”?

STAR*D: The Harms of Orchestrated Psychiatric Fraud

Stay Connected